Hospira, Inc. announced that it has launched its generic version of The Medicines Company's (MDCO - Free Report) Angiomax (bivalirudin for injection). Hospira’s product is available in a single-dose flip-top vial, similar to The Medicines Co.’s branded product.
Hospira also plans to launch a differentiated presentation of the 250 mg dosage using its unique ADD-Vantage vial.
The product is indicated for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty or coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor as listed in the REPLACE-2 study. In addition, it is indicated for use in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS), who are undergoing PCI.
The entry of Hospira’s generic version was expected earlier this month. The Medicines Co. had received an unfavourable ruling in the U.S. Court of Appeals for the Federal Circuit Court. In fact, shortly after the court ruling, the Medicines Co. announced an agreement with Sandoz Inc. for the distribution of an authorized generic of Angiomax in the U.S.
While Angiomax sales were about $500 million in the U.S. in 2014, sales dropped significantly in the first quarter and are expected to decline further in the second quarter of 2015.
The Medicines Co. has been working on diversifying its revenue stream and is focusing on the launch of its recently approved products including Kengreal, Ionsys , Orbactiv and a new formulation of Minocin IV.
Hospira currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Eleven Biotherapeutics, Inc. (EBIO - Free Report) and AMAG Pharmaceuticals, Inc. (AMAG - Free Report) , each carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>